Ascelia Pharma's Phase III SPARKLE study results evaluating Orviglance, a liver-specific MRI contrast agent, have been accepted for presentation at the Radiological Society of North America (RSNA) annual conference in December. The data, previously announced in May, will be featured as Cutting-Edge Research during an oral presentation on December 2.
The SPARKLE trial investigated the efficacy and safety of Orviglance in patients with severe kidney disease undergoing liver MRI. This patient population often faces challenges as gadolinium-based contrast agents are typically contraindicated due to the risk of nephrogenic systemic fibrosis (NSF).
Potential of Orviglance
Dr. Beatrice L. Madrazo stated, "The results support the potential clinical value of a new manganese-based liver-specific MRI contrast option for patients with severe kidney disease." Orviglance, a manganese-based contrast agent, offers a potential alternative for these patients, addressing a critical unmet need in diagnostic imaging.
The acceptance of the SPARKLE study for presentation at RSNA, a leading radiology conference, underscores the importance of the findings and the potential impact of Orviglance on clinical practice. The presentation will provide a platform for further discussion and dissemination of the study results among radiologists and other healthcare professionals.
